These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 9413494)

  • 21. Analyses of cost data in economic evaluations conducted alongside randomized controlled trials.
    Doshi JA; Glick HA; Polsky D
    Value Health; 2006; 9(5):334-40. PubMed ID: 16961551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report.
    Ramsey SD; Willke RJ; Glick H; Reed SD; Augustovski F; Jonsson B; Briggs A; Sullivan SD
    Value Health; 2015 Mar; 18(2):161-72. PubMed ID: 25773551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regression methods for cost-effectiveness analysis with censored data.
    Willan AR; Lin DY; Manca A
    Stat Med; 2005 Jan; 24(1):131-45. PubMed ID: 15515137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Non-parametric methods for estimating confidence intervals around the incremental cost-effectiveness ratio].
    Petrinco M; Gregori D; Lazzarato F; Brunello F; Veltri A; Berchialla P; Pagano E
    Epidemiol Prev; 2008; 32(6):307-13. PubMed ID: 19353965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimating incremental cost-effectiveness ratios and their confidence intervals with differentially censored data.
    Wang H; Zhao H
    Biometrics; 2006 Jun; 62(2):570-5. PubMed ID: 16918922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of health research study participant recruitment strategies: a systematic review.
    Huynh L; Johns B; Liu SH; Vedula SS; Li T; Puhan MA
    Clin Trials; 2014 Oct; 11(5):576-83. PubMed ID: 24980278
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessing the relative efficacy of new drugs: an emerging opportunity.
    Eichler HG; Thomson A; Eichler I; Schneeweiss S
    Nat Rev Drug Discov; 2015 Jul; 14(7):443-4. PubMed ID: 26129789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models.
    Manca A; Rice N; Sculpher MJ; Briggs AH
    Health Econ; 2005 May; 14(5):471-85. PubMed ID: 15386662
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A pragmatic multicentered randomized controlled trial of yoga for chronic low back pain: economic evaluation.
    Chuang LH; Soares MO; Tilbrook H; Cox H; Hewitt CE; Aplin J; Semlyen A; Trewhela A; Watt I; Torgerson DJ
    Spine (Phila Pa 1976); 2012 Aug; 37(18):1593-601. PubMed ID: 22433499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Putting clinical trials into context.
    Hyde C; Stanworth S; Brunskill S; Murphy M
    Lancet; 2005 Sep 17-23; 366(9490):980-1. PubMed ID: 16168771
    [No Abstract]   [Full Text] [Related]  

  • 31. A systematic review of cost-effectiveness analyses alongside randomised controlled trials of acupuncture.
    Kim SY; Lee H; Chae Y; Park HJ; Lee H
    Acupunct Med; 2012 Dec; 30(4):273-85. PubMed ID: 23099289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What's cost-effective in cancer care?
    Cancer Discov; 2011 Nov; 1(6):OF1-2. PubMed ID: 22586658
    [No Abstract]   [Full Text] [Related]  

  • 33. Nonparametric inference for time-dependent incremental cost-effectiveness ratios.
    Yee LM; Gary Chan KC
    Stat Med; 2015 Dec; 34(30):4057-69. PubMed ID: 26215727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical trials: where do we go from here?
    Cruess AF; Ballantyne M
    Can J Ophthalmol; 1992 Feb; 27(1):3-5. PubMed ID: 1555133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cost effectiveness of a randomized controlled trial to establish the relative efficacy of vitamin K1 compared with alendronate.
    Stevenson MD; Jones ML
    Med Decis Making; 2011; 31(1):43-52. PubMed ID: 20375420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis using data from multinational trials: the use of bivariate hierarchical modeling.
    Manca A; Lambert PC; Sculpher M; Rice N
    Med Decis Making; 2007; 27(4):471-90. PubMed ID: 17641141
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Psychopharmacology: the need for effectiveness trials to inform evidence-based psychiatric practice.
    Lagomasino IT; Dwight-Johnson M; Simpson GM
    Psychiatr Serv; 2005 Jun; 56(6):649-51. PubMed ID: 15939939
    [No Abstract]   [Full Text] [Related]  

  • 38. Analyzing overall survival in randomized controlled trials with crossover and implications for economic evaluation.
    Jönsson L; Sandin R; Ekman M; Ramsberg J; Charbonneau C; Huang X; Jönsson B; Weinstein MC; Drummond M
    Value Health; 2014 Sep; 17(6):707-13. PubMed ID: 25236994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trial that pays patients to take antipsychotic drugs comes under attack.
    Eaton L
    BMJ; 2009 Oct; 339():b4202. PubMed ID: 19822620
    [No Abstract]   [Full Text] [Related]  

  • 40. The cost-effectiveness of an RCT to establish whether 5 or 10 years of bisphosphonate treatment is the better duration for women with a prior fracture.
    Stevenson MD; Oakley JE; Lloyd Jones M; Brennan A; Compston JE; McCloskey EV; Selby PL
    Med Decis Making; 2009; 29(6):678-89. PubMed ID: 19509121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.